Biomarker Directed Trial of Temozolomide and Stenoparib in Relapsed SCLC

NCT06681220 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

166

Enrollment

FED

Sponsor class

Conditions

Relapsed Small Cell Lung Cancer
Recurrent Small Cell Lung Cancer

Interventions

COMBINATION_PRODUCT: Stenoparib/Temozolomide
DRUG: Lurbinectedin
COMBINATION_PRODUCT: Stenoparib/Temozolomide

Sponsor

VA Office of Research and Development